<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03535610</url>
  </required_header>
  <id_info>
    <org_study_id>SC-ES_001</org_study_id>
    <nct_id>NCT03535610</nct_id>
  </id_info>
  <brief_title>Uterine Artery Embolization With Microspheres in Patients With Leiomyoma.</brief_title>
  <acronym>EMBOSOFT I</acronym>
  <official_title>Uterine Artery Embolization With Microspheres in Patients With Leiomyoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scitech Produtos Medicos Ltda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scitech Produtos Medicos Ltda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the therapeutic response to uterine artery embolization in 30 patients with
      leiomyoma using the microspheres Embosoft (EmbosoftÂ® - Scitech Medical).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2, 2018</start_date>
  <completion_date type="Anticipated">March 20, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, single-arm, open label study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uterine Volume Reduction</measure>
    <time_frame>6 months</time_frame>
    <description>Uterine Volume Reduction measured by MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fibroid Reduction</measure>
    <time_frame>6 months</time_frame>
    <description>Fibroid Reduction measured by MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Improvement</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of Life Improvement measured by UFS-QOL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian Function</measure>
    <time_frame>6 months</time_frame>
    <description>Ovarian Function measured by Anti-Mullerian Hormon dosage pre and post-procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Uterine Leiomyoma</condition>
  <arm_group>
    <arm_group_label>Embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Uterine Embolization with PVA Microspheres</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Uterine Embolization</intervention_name>
    <description>Uterine Embolization with PVA Microspheres</description>
    <arm_group_label>Embolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female patients from 18 to 50 years old;

          -  symptomatic uterine intramural leiomyomas or multiple symptomatic leiomyomas in the
             presence of intramural;

          -  patient agrees with study procedures;

          -  patient signs the informed consent form.

        Exclusion Criteria:

          -  asymptomatic women;

          -  isolated adenomyosis, pediculated subserous myoma, submucous leiomyoma (50% of uterine
             cavity diameter), intraligamentous leiomyoma;

          -  leiomyoma diameter higher than 10 cm;

          -  leiomyoma above the umbilical scar;

          -  endometrial neoplasia or hyperplasia or presence of any malignancy

          -  pregnant or breast feeding women;

          -  active vasculitis;

          -  pelvic irradiation history;

          -  uncontrolled coagulopathies;

          -  renal insufficiency;

          -  contrast allergy;

          -  concomitant use of GnRH analogues.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female patients with Uterine Leiomyoma</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>May 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Embolization</keyword>
  <keyword>Uterine Leiomyoma</keyword>
  <keyword>Embospheres</keyword>
  <keyword>Microspheres</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

